DMHCA

DMHCA, a potent and selective LXR agonist, specifically activates the cholesterol efflux arm of the LXR pathway without stimulating triglyceride synthesis. DMHCA has anti-inflammatory effects and can be used for the research of cholesterol homeostasis diabetes[1].

Product Specifications

CAS Number

[79066-03-8]

UNSPSC

12352211

Target

LXR

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/dmhca.html

Purity

99.91

Solubility

DMSO : 7.69 mg/mL (ultrasonic)

Smiles

C[C@@]12[C@](CC[C@]2([H])[C@H](C)CCC(N(C)C)=O)([H])[C@@]3([H])[C@@](CC1)([H])[C@@]4(C(C[C@H](CC4)O)=CC3)C

Molecular Formula

C26H43NO2

Molecular Weight

401.63

References & Citations

[1]Cristiano P Vieira, et al. Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes. JCI Insight. 2020 Jul 9;5 (13) :e137230.